12-mm Partially Covered vs Bare Self-Expandable Stents for Malignant Distal Biliary Obstruction
Official title: 12-mm Partial Covered Versus Bare Self-Expandable Metallic Stents for Malignant Distal Biliary Obstruction: A Prospective, Randomized Clinical Study
Run by Chung-Ang University Hospital · NCT07559968 · Data updated 2026-11-12
This study tests whether a 12-mm partially covered self-expandable stent works better than a 12-mm bare self-expandable stent for patients with unresectable malignant distal biliary obstruction who have already had PTBD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Chung-Ang University Hospital Academic / other |
| Locations | 1 site (Seoul, Seoul) |
| Status | Recruiting |
| Started | May 27, 2026 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT07559968 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 19 years and older with unresectable malignant distal biliary obstruction who have already undergone PTBD and are planned for metallic stent placement through the PTBD tract.
✕Probably not a fit
Patients with prior biliary metallic stent placement, hilar obstruction, or other major biliary lesions may not benefit from the study interventions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, randomized trial compares two 12-mm self-expandable metallic stents in adults with unresectable malignant distal biliary obstruction who have undergone PTBD. Participants are randomly assigned to receive either a partially covered or a bare stent through the existing PTBD tract and are followed for 12 months with assessments at 3, 6, and 12 months. Outcomes include recurrent biliary obstruction, stent patency, need for reintervention, overall survival, and procedure-related complications. The study aims to provide evidence to guide selection of the more effective and safe 12-mm stent type in this palliative setting. It is a single-center trial sponsored by Chung-Ang University Hospital with collaboration from OSYMED Co., Ltd.
Why it matters
Potential benefit: If successful, the trial could identify the stent type that provides longer patency and fewer complications, improving quality of life for patients with unresectable malignant distal biliary obstruction.
How similar studies have gone: Previous work has explored 10-mm stents with mixed results; this trial extends evaluation to 12-mm stents to determine comparative effectiveness and safety.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who voluntarily provide written informed consent after receiving sufficient explanation of the study purpose, methods, and potential benefits and risks * Adults aged 19 years or older * Patients diagnosed with unresectable malignant distal biliary obstruction based on imaging studies (CT, MRI, ERCP, etc.) or histologic confirmation * Patients who have already undergone percutaneous transhepatic biliary drainage (PTBD) according to the institutional clinical protocol and are scheduled for metallic stent placement through the existing PTBD tract Exclusion Criteria: * Patients with a previous history of biliary metallic stent placement * Patients with upper biliary obstruction (hilar level or above) * Patients with other major biliary lesions in addition to malignant distal biliary obstruction * Patients for whom the investigator judges that study conduct or data collection would be markedly difficult
Where it's running
-
Chung-Ang university Hospital
Seoul, Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Woosun Choi, MD, PhD — Associate Professor, Department of Radiology, Chung-Ang University Hospital
- Study coordinator: Woosun Choi, MD, PhD
- Email: radiochoi527@gmail.com
- Phone: +82-2-6299-2681
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endoscopic Ultrasound-Guided Hepaticogastrostomy With or Without Antegrade Stenting for Malignant Distal Biliary Obstruction
This trial tests whether adding antegrade stenting to EUS-guided hepaticogastrostomy helps longer-lasting relief of malignant distal biliary obstruction compared with hepaticogastrostomy alone in adults who cannot have ERCP.
-
EUS-guided pancreaticobiliary procedures with the RIVOS access device
This study tests how the RIVOS EUS access device performs during interventional procedures for pancreatic and bile duct problems in adults.
-
Sedation Methods in PTBD: How Two Regimens Compare for Quality and Recovery
This study tests two sedation plans (propofol with remifentanil vs propofol with ketamine) to see which helps patients recover faster after PTBD while staying comfortable and safe.
-
Suprapapillary Metal Stent vs. Routine Drainage for Malignant Hilar Biliary Obstruction
This trial tests whether placing a self-expanding metal stent above the papilla works better than the standard transpapillary drainage for patients with cancer-caused bile duct blockage near the liver.
-
Intraductal antibiotic given during ERCP for acute cholangitis
This trial tests whether putting an antibiotic directly into the bile ducts during ERCP, together with standard IV antibiotics, helps adults with mild-to-moderate acute cholangitis recover faster and avoid worsening infection compared with IV antibiotics alone.
-
Mechanical versus electrocautery dilator for EUS-guided biliary drainage
This trial will test whether using a mechanical dilator instead of an electrocautery dilator reduces bleeding during EUS-guided biliary drainage for patients with biliary obstruction after failed ERCP.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.